

Northern Ireland  
Cancer Registry

# Northern Ireland Cancer Registry

## Annual Operational Report 2024

*Providing information on Cancer for Planning,  
Development, Research and Education*



## CONTEXT

The Northern Ireland Cancer Registry (NICR) produces an Annual Operational Report which sets out an overview of the Registry's work in the previous year (April 2023 - March 2024), the Registry's role, direction and priorities for the year ahead and it holds to the vision, purpose and values set out in the NICR 5-Year Strategic Plan (April 2019 – March 2024) approved by the NICR Steering Group.

The Operational Report comes at a time of positive changes in the Registry;

- We celebrate the 30<sup>th</sup> Anniversary of Registry coming into existence
- Investment from DOH to facilitate Routes to Diagnosis annual reporting,
- The IT system, which has been in place for 20 years, is in the process of replacement.

## Contents

<b>GLOSSARY</b> .....	<b>4</b>
<b>1. INTRODUCTION</b> .....	<b>6</b>
1.1 Background .....	6
1.2 NICR Vision .....	6
1.3 NICR Purpose .....	6
1.4 NICR Values .....	6
1.5 NICR Objectives .....	6
1.6 Ethics and Data Protection .....	10
1.7 NICR engages with patients by: .....	11
1.8 NICR links with the public by: .....	11
1.9 NICR links with clinical teams by: .....	11
1.10 NICR links with researchers through: .....	11
1.11 NICR engages with policy makers by: .....	12
1.12 Information Security .....	12
<b>2. METHOD OF OPERATION</b> .....	<b>13</b>
2.2 Diseases Registered .....	13
2.1 Data Sources .....	13
<b>3. REGISTRY IT SYSTEM</b> .....	<b>18</b>
3.1 Background .....	18
3.2 Method of Data Processing .....	18
<b>4. REGISTRY OUTPUTS</b> .....	<b>19</b>
4.1 Official Statistics .....	19
4.3 Cancer Factsheets .....	20
4.4 Research Publications .....	20
4.5 Information Requests .....	20
4.6 Reports .....	21
4.7 Other Uses of Registry Data .....	21
4.8 Research Projects .....	21
<b>5. ISSUES OF CONCERN AND CHALLENGES FOR NICR</b> .....	<b>23</b>
5.1 Lack of a Legislative Framework for Disease Registration .....	23
5.2 Access to Data Sources .....	23
5.3 IT System .....	23
5.4 Annual Funding .....	24
5.5 Funding for Audits .....	24
5.6 Staffing and Succession Planning .....	24
<b>6. NICR RESOURCES</b> .....	<b>25</b>
6.1 Current staff and funding .....	25
6.2 Allocations from PHA .....	26
6.3 Other funding .....	26
<b>Update on Actions for 2023-2024</b> .....	<b>27</b>
<b>NICR Key Priorities 2024-2025</b> .....	<b>29</b>
<b>REFERENCES</b> .....	<b>33</b>
<b>APPENDIX A: Steering Group, Council and Research Advisory Group Membership and Role</b> .....	<b>35</b>
<b>APPENDIX B: Patient Information Leaflet</b> .....	<b>37</b>
<b>APPENDIX C: Performance Indicators for 2020</b> .....	<b>38</b>
<b>APPENDIX D: Peer reviewed publications</b> .....	<b>39</b>
<b>APPENDIX E: Requests for Information</b> .....	<b>41</b>
<b>APPENDIX F: NICR Media</b> .....	<b>43</b>

## GLOSSARY

<b>Acronym</b>	<b>Definition</b>
BSO	Business Services Organisation
APG	All Party Group
AQs	Assembly Questions
BO	Barrett's Oesophagus
CGIN	Cervical Glandular Intraepithelial Neoplasia
CIN	Cervical Intraepithelial Neoplasia (grades 1-3)
CIO	Cancer Intelligence Officer
COIS	Clinical Oncology Information System
COSD	Cancer Outcomes Services Dataset
CPH	Centre for Public Health
CRG	Clinical Reference Group
CRUK	Cancer Research United Kingdom
DHSS	Department of Health & Social Services
DoH	Department of Health
DPIA	Data Privacy Impact Assessment
ECIS	European Cancer Information System
ENCR	European Network Cancer Registries
EPD	Enhanced Prescribing Database
ER	Estrogen Receptor
GAIN	Guidelines and Audit Implementation Network
GDPR	General Data Protection Regulation
GRONI	General Register Office NI
HSC	Health & Social Care
HSCIMS	Health and Social Care Inequalities Monitoring System
HSCNI	Health & Social Care NI
ICBP	International Cancer Benchmarking Partnership
ICD03	International Classification of Diseases for Oncology Third Edition
ICD10	International Classification of Diseases and Health Related Problems Tenth Revision
ISMS	Information Security Management System
KPIs	Key Performance Indicators
LIMS	Laboratory Information Management System
LSHTM	London School of Hygiene and Tropical Medicine
MGUS	Monoclonal Gammopathy of Undetermined Significance
NCRAS	National Cancer Registration Service
NI	Northern Ireland
NICaN	NI Cancer Network
NICC	NI Cancer Centre
NICR	NI Cancer Registry
NINIS	NI Neighbourhood Information Service
NIPCLR	NI Premalignant Cervical Lesions Register
NMSC	Non-Melanoma Skin Cancer
NWCC	North West Cancer Centre
OAC	Oesophageal Adenocarcinoma

OPCS4	Office of Population Censuses and Surveys Classification of Surgical Operations Version 4
ORECNI	Office for Research Ethics Committees Northern Ireland
PAS	Patient Administrative System
PGJCCR	Patrick G. Johnston Centre for Cancer Research
PHA	Public Health Agency
PPI	Patient and Public Involvement
PQs	Parliamentary Questions
QUB	Queen's University Belfast
RAG	Research Advisory Group
RD	Rapid Datasets
RISOH	Regional Information System for Oncology and Haematology
RPA	Review of Public Administration
RQIA	Regulation and Quality Improvement Authority
SACT	Systemic Anti-Cancer Therapy
SEHSCT	South Eastern Health and Social Care Trust
SMILE	Stratified Mucin-producing Intraepithelial Lesion
SPPG	Strategic Planning and Performance Group ( <i>formerly HSCB – Health and Social Care Board</i> )
TNM	International Union Against Cancer TNM Classification of Malignant Tumours
UAT	User Acceptance Testing
UKIACR	UK and Ireland Association of Cancer Registries

## **1. INTRODUCTION**

### **1.1 Background**

Cancer registries are responsible for the collection, collation and analysis of data relating to incidence, prevalent, mortality and survival of cancer in patients resident in a defined population. NICR is one of five cancer registries that cover the populations of Great Britain and Ireland. These registries use common definitions and processes and share the same main objective; to deliver timely, comparable high-quality cancer data. In 1959 the Northern Ireland (NI) Department of Health & Social Services (DHSS) established a paper-based cancer registry. This was largely incomplete due to the lack of requirement on clinicians to notify new cancer diagnoses and the limited resources allocated to its function.

NICR was established in 1994 to provide information on cancers (from 1993) in the NI population for the purposes of planning, research, education and evaluation of services. Following the Review of Public Administration (RPA), funding for the Registry moved from a five-year cycle with DHSS to an annual cycle with the Public Health Agency (PHA) in 2009. The Registry operates under an agreement between the PHA and Queen's University Belfast (QUB) (available on request) which sets out the terms by which the University maintains and operates a register of incident cancers. NICR has had regular peer reviews to ensure quality and advice on direction, with the last review (2018) available [here](#).

### **1.2 NICR Vision**

To continually improve cancer intelligence in NI for the benefit of patients.

### **1.3 NICR Purpose**

To provide accurate, timely information on cancers and pre-malignant conditions occurring in NI for official statistics, research, education, service planning, monitoring and evaluation.

### **1.4 NICR Values**

- Ensure high quality data with complete ascertainment of cases,
- Protect the confidentiality of data held,
- Work with those who aim to reduce cancer burden in our society,
- Work together as a team,
- Value and develop our staff,
- Engage with patients and their representatives,
- Provide value for money.

### **1.5 NICR Objectives**

- Collect and confidentially store accurate, timely and comprehensive data on cancers and selected pre-malignant conditions occurring in the NI population,
- Uphold patient and carer confidentiality using strict data security measures to ISO27001 standards,
- Analyse data to support NICR's role as provider of official statistics for cancer incidence, prevalence and survival,
- Develop the Routes to Diagnosis methodology for Cancer Patients in NI,
- Facilitate monitoring of the impact of cancer screening services in NI,

- Provide appropriate information for ad hoc cancer queries including investigation of alleged cancer clusters, subject to funding,
- Undertake and assist audits of cancer treatments, services and outcomes, and recommend improvements in cancer services where appropriate,
- Facilitate planning of cancer services for prevention, diagnosis, cure and care,
- Promote, facilitate and undertake research into cancer causes, prevention, treatments, outcomes, care and survivorship, subject to funding
- Publish scientific reports and research articles relating to cancer, in line with point above,
- Promote professional and public awareness about cancer,
- Link nationally and internationally to promote cancer registration and increase understanding and management of cancer.

NICR is supported by a Steering Group (Management), which oversees the work of the Registry and a Council, appointed by the Steering Group, which advises the Director and Steering Group on matters such as NICR outputs and which provides a mechanism for the Registry to link with its key stakeholders twice annually. In 2019 a Research Advisory Group was established with clinical, scientific and patient representation – this Group and its activities were merged with the Council in 2021. (See [Appendix A](#) for membership of Steering Group, Council and Research Advisory Group).


Cancer registry processes include data acquisition, linkage, quality assurance and analysis to ensure that data on cancers and premalignant diseases are fit for purpose including:

- The provision of annual official statistics on cancer incidence, prevalence and survival,
- Disease surveillance,
- Planning and administration of cancer related health care,
- Monitoring and audit of cancer related health and health care provision and outcomes,
- Provision of information to the Genetics Counselling Services on those with potential predisposition to certain cancer types,
- Quality assurance of population-based screening programs,
- Investigation of alleged cancer clusters,
- Provision of data for, and undertaking research into, prevention, patterns and trends and outcomes of cancer, approved by research ethics committees when required,
- Improving awareness of the NI cancer burden in NI and cancer prevention.

In 2021 NI had an estimated population of 1,904,500. Excluding non-melanoma skin cancer (NMSC) on average 9,843 cancers were diagnosed each year during 2016-2020 (13,684 cases per year including NMSC). At the end of 2020 there were 69,168 cancer survivors (excluding NMSC) residing in NI who had been diagnosed in the previous 25 years (i.e. 1996-2020) (102,027 including NMSC).

Cancer incidence is increasing, with the increase predicted to continue, largely due to an ageing population amongst whom cancer risk is higher. In 1993 there were 6,265 cancer cases (excluding NMSC) diagnosed. By 2020 this had risen to 9,273 cancer cases, an increase of 48%, (an additional 3,172 cases of NMSC). It is predicted this will increase to 14,238 incident cancer cases (excluding NMSC) by 2040 (Figure 1).


Figure 1: Cancer incidence projections for NI (excluding NMSC)




Since the NICR began in 1994, the number of data items collected and processed has increased substantially from 44 in 1993-96 to almost 200 in recent years. This number varies depending on tumour site and whether clinical audit is undertaken. Alongside this increase in cancer cases the level of detail and complexity of cancer data of has increased dramatically. For example the number and proportion of cancer cases which have been staged are shown in Figures 2a and 2b, increasing from only 1,087 in 1993 to 7,958 in 2020, which represents an increase from just over 10% in 1993 to almost 70% in recent years (Figure 2a and 2b).



**Figure 2a: Malignant Cancers Staged vs Unstaged**



**Figure 2b: Malignant Cancers Staged vs Unstaged**



As NICR looks to the future we anticipate substantial increases in the quantity of data potentially available to collect and process as diagnostic methods improve, with more emphasis on patient pathway analysis and individual tumour level data. Examples of extra data requirements include viral and biomarkers and data on disease progression. We have monitored the impact of COVID-19 on cancer services, cancers diagnosed, method of presentation, stage and survival via reports published on a monthly basis.

In addition, there continues to be change and development with health service ENCOMPASS systems, the most significant for cancer registration being the planned introduction of the integrated patient record, which was rolled out to the SEHSCT in 2023 and further roll out to the BHSCT in May 2024.

We receive data from RISOH in the form of monthly downloads of Systemic Anti-Cancer Therapy (SACT). These datasets are very important to enable completion of treatment details on all patients for production of cancer intelligence and official statistics. Unfortunately, we still have not obtained read-only access to RISOH despite NICR's data sharing agreements with the Trusts. This access is essential for confirmation of NICR data on diagnosis, stage, treatment and disease progression. We are awaiting access since RISOH replaced COIS in 2018 and have been advised this will be granted following the BSO CITRIX upgrade for third party access.

## **1.6 Ethics and Data Protection**

In October 2020, NICR had Ethical Approval for its databases renewed for five years from the Office for Research Ethics Committees NI (ORECNI), Reference 20/NI/0132. Research projects using non-routine data is required to have separate ethical approval.

NICR is a registered data controller under Queen's University Belfast with the Information Commissioner's Office (Registration Number: Z6833827) and has undertaken a Data Privacy Impact Assessment (DPIA) to align with UK GDPR (General Data Protection Regulation) and other relevant data protection laws. In addition, NICR has achieved ISO27001 accreditation for its information security management system (ISMS), which is maintained by a NICR staff member who oversees compliance and completion of regular internal audits.

NICR has data sharing agreements to facilitate receipt of data from NI Health and Social Care Trusts, Business Services Organisation and the PHA Cancer Screening Service. The Registry does not seek individual patient consent for data collection. However, if requested, we would retain the anonymised fact of the cancer but remove the patient's identifiable information from the NICR database. No such requests have been received since the Registry was launched in 1994. Information on opting out is included in the patient information leaflet ([Appendix B](#)).

We welcomed the Health and Social Care Secondary Use of Data legislation in April 2016 and have been awaiting development of the regulations, which may affect the operation of the NICR. The potential adverse impact that blanket patient opt-out would have on completeness for a population-based cancer registry like NICR needs to be considered and the exemptions introduced to address opt-out for cancer registration in England should be applied.

All identifiable data are held in a secure area of the registry, available to only a small group of Registry staff for data verification and addition of specified clinical information such as cancer stage.

Patient identifiable data are required to:

- Allow validation of data received from multiple sources,
- Enable linkage of cases for follow up e.g., death records for survival, multiple tumours in same patient and to avoid double counting,
- Enable linkage to other databases e.g., treatment, screening,
- Support the Genetic Advice Service,
- Facilitate recall exercises. For example, the NICR previously helped the Department of Health (DoH) to identify patients who were at increased risk of breast cancer following radiation therapy for lymphoma with these patients subsequently offered screening mammograms.

### **1.7 NICR engages with patients by:**

- Patient representation on the NICR Steering Group and Council,
- Cancer charity funding of research in NICR, with associated PPI,
- Presenting NICR information to cancer patient groups,
- Including patients in report launches and studies.

### **1.8 NICR links with the public by:**

- NICR has a leaflet and a poster to inform patients, clinicians and the public about its work. These have been distributed widely across NI for display in cancer centres/units/GP surgeries/charities and are available on the NICR website ([Appendix B](#)),
- A video was developed to inform a wider audience of the work of the NICR which is available [here](#),
- Public awareness of NICR through NI media by regular appearance of staff on TV and radio interviews highlighting cancer statistics and changes in survival, while encouraging early detection of cancers ([Appendix E](#)),
- NICR has an active [X](#) account sharing relevant information on various cancer sites during key awareness periods along with updates on Registry outputs and publications.

### **1.9 NICR links with clinical teams by:**

- Attending NI Cancer Network (NICaN) Board meetings,
- Attending NICaN Clinical Reference Group (CRG) meetings,
- Attending the Encompass Cancer Care Decision Group,
- Involvement in cancer audits – developing funding applications, determining the datasets to be collected, interpretation of results and making recommendations,
- Working with clinicians on research projects as collaborators, advisors and/or funded participants e.g., for pathological verifications,
- Having clinicians as active members of the NICR Council and Steering Group,
- Providing information for genetics counselling requests,
- Providing feedback to cancer screening services for quality assurance and improvement purposes.

### **1.10 NICR links with researchers through:**

- Interim Director and current Acting Deputy Director being academic research staff in QUB,
- Provision of designated area within NICR for researchers to access anonymised datasets,
- Inclusion of local, national and international researchers on specific research projects,
- Preparation of joint applications for research grant funding,
- Provision of data through data requests and data available on the NICR website,
- Providing data to international consortia for international studies e.g., [Eurocare](#), [Concord](#), [International Cancer Benchmarking Partnership \(ICBP\)](#), [Cancer Incidence in V Continents](#), [Benchista](#),
- Working collaboratively with local, national and international researchers on externally held grants,
- Publication of adaptations from official statistics, audit reports and peer reviewed publications,
- Training of junior researchers through summer studentships and facilitation of undergraduate and postgraduate dissertation project work.

### **1.11 NICR engages with policy makers by:**

- Development of [Routes to Diagnosis](#) on behalf of the DoH ,
- Providing timely information on the impact of COVID-19 on cancer services via regular [reports](#),
- Providing timely and accurate answers to NI Assembly Questions (AQs), Parliamentary Questions (PQs) and data requests from Trusts, PHA and DoH,
- Attendance at relevant NI Assembly Health Committee events (e.g., All Party Group (APG) on Cancer),
- Working with NICaN on specific projects,
- Working with PHA on specific projects e.g., 2019-2020 Breast Treatment Services as required by the DoH,
- Providing data for development of the 2022-2032 NI Cancer Strategy,
- Participation in the DoH Cancer Data Steering Group and Cancer Strategy Steering Group,

### **1.12 Information Security**

The NICR operates a high level of security, which has been independently audited and certified to meet the ISO27001:2013 Information Security Management standard in May 2017 and recertified in February 2020 and again in May 2023. Compliance is audited throughout the year both internally and externally.

Information security controls include physical measures such as video surveillance, staff card tiered access system, alarms triggered out of hours and door codes which are changed regularly and immediately after a member of staff ceases NICR employment. There are a number of administrative controls implemented by means of various policies and procedures (available in Registry). These are included in regular staff training in addition to having their implementation regularly audited.

A User Access control system provides a tiered system of access to various physical areas of the Registry with only approved staff allowed in areas where patient identifiable data are used to verify registrations. A designated area for NICR staff working with anonymised patient level data and a separate designated hot desk facility for external researchers using anonymised Registry data are available. Phones and electronic devices are left at reception when external researchers access the Registry hot desk facility.

Staff can avail of hybrid working but while working off site, staff must adhere to security controls as per the NICR Home Working Policy.

A limited number of NICR staff use hscni.net email accounts for secure communication and transfer of data with the NI Health & Social Care. Similarly, nhs.net email accounts are in place for communication and data transfers between NICR and NHS organisations. The HSCNI encrypted email service is used to securely transfer data to external research organisations.

NICR is working with an external IT company to develop a new IT system to replace PRAXIS, the NICR's current cancer registration system originally developed 20 years ago. The new system is being developed using modern database technologies which will be more easily supported going forward.

## **2. METHOD OF OPERATION**

### **2.2 Diseases Registered**

NICR registerable tumours are:

- Invasive malignancies including NMSC (ICD 10: C00-C97),
- In-situ lesions (ICD10: D00-D09),
- Benign brain and testicular conditions (ICD10: D32, D33, D35.2, D35.3, D35.4 and D29.2),
- Neoplasms of uncertain or unknown behaviour (ICD10: D37-D48).

### **2.1 Data Sources**

NICR acquires cancer and pre-malignant diagnoses via electronic downloads from pathology laboratories, hospital inpatient records, multi-disciplinary team meeting databases and death registrations.

#### ***Pathology***

NICR Cancer Intelligence Officers (CIO) use these sources to extract complex clinical information such as cancer staging and by following cancer registration guidance ensure the availability of accurately coded population-based cancer data for NI. CIOs have access to full pathology text reports and part of their resolving work requires reading reports to obtain full staging and diagnostic information that may not be available from electronic downloads or not coded to cancer registration standards.

In addition to the data sources above NICR has access to datasets on:

#### ***Prescriptions***

The Enhanced Prescribing Database (EPD), managed by Business Services Organisation (BSO), contains detailed information on primary care prescriptions dispensed to patients in NI since March 2008. The dataset is used to identify specific cancer treatments such as hormone therapy for breast and prostate cancer. It also provides limited information on co-morbidities within the cancer patient population in NI, through the use of prescriptions for specific comorbid conditions.

#### ***Comorbidities***

Since 1<sup>st</sup> January 2006, NICR has received PAS downloads of hospital admission and discharge records for cancer patients, which provide hospital-based records of patient comorbidities.

#### ***Surgery***

Curative surgical codes for Cancer Registration have been defined by the UK and Ireland Association of Cancer Registries (UKIACR) Analysis group. NICR uses Office of Population Censuses and Surveys Classification of Surgical Operations (Version 4.4) (OPCS4) codes to extract surgical data from PAS hospital discharge data.

#### ***Chemotherapy***

Chemotherapy data are available from PAS hospital discharge data using OPCS4 procedure codes and are supplemented by extracts received from the Regional Information System for Oncology and Haematology (RISOH).

## **Radiotherapy**

NICR receives radiotherapy treatment data from both the Northern Ireland Cancer Centre (NICC) in Belfast and the North West Cancer Centre (NWCC) in Altnagelvin, as well as limited radiotherapy notifications received through PAS hospital discharge data using OPCS4 procedure codes.

## **Pre-malignant Disease Registers**

The NICR also holds the following pre-malignant disease registers whose upkeep depends on external grant funding:

- Barrett's Oesophagus,
- Colorectal polyps,
- Endometrial Hyperplasia,
- Monoclonal Gammopathy of Undetermined Significance (MGUS),
- High grade CIN, CGIN and SMILE.

The importance of these pre-malignant registers was highlighted in the NI Cancer Strategy 2022-2032<sup>1</sup>, which advised that "expansion of the precancerous databases would enable improved patient outcomes.". Action 11 from the Strategy recommended creation of "surveillance systems for conditions where there is clear evidence regarding the pre-malignant potential of a particular condition to ensure people are not lost to follow up."

See below for further detail on the researcher-led pre-malignant registries.

## **NI Barrett's Oesophagus**

The NI Barrett's Oesophagus Register is one of the largest population-based registers of Barrett's oesophagus worldwide, and now includes information on more than 24,500 incident cases diagnosed in Northern Ireland between 1993 and 2018. Barrett's oesophagus is a pre-cursor condition for oesophageal adenocarcinoma and the register has provided data for publications of international standing<sup>6-14</sup>. The register is the foundation for a large body of epidemiological, clinical, and biomarker research, now led by Professor Helen Coleman's team, that has informed clinical guidelines for the surveillance of Barrett's oesophagus patients. The current epidemiological work aims to investigate trends in diagnoses of Barrett's oesophagus, and progression to dysplasia and oesophageal adenocarcinoma, now that new endoscopic treatments such as Endoscopic Mucosal Resection (EMR) and Radiofrequency ablation (RFA) are available and the current biomarker studies, which use the NIBR as a sampling frame, aim to: (i) explore the potential of a biomarker for assessing molecular age of Barrett's (led by Prof. Helen Coleman in collaboration with Dr Kit Curtius, UCSD and Professor AJ McKnight, CPH) and (ii) identify biomarkers associated with progression to oesophageal adenocarcinoma (led by Dr Richard Turkington and Professor Helen Coleman).

In 2019, a dedicated NI Barrett's research Patient and Public Involvement (PPI) group was established and is comprised of five patients affected by the condition. The PPI group meet quarterly to guide research and at their first meeting in June 2019, identified an 'unmet' need for evidence-based information on Barrett's oesophagus at diagnosis. Over the past two years, the PPI group together with the NI Barrett's research team have co-produced a patient information leaflet which has received very positive feedback from both patients and clinical staff. The final leaflet has been disseminated to endoscopy clinics in NI and the co-production of the leaflet is currently being written up as a scientific paper.

In January 2023, Breakthrough Cancer Research launched the first All-Ireland Oesophageal Cancer Network (AllCaN Oesophageal) and has invested €1 million in Oesophageal Cancer research on the island of Ireland with the aim of significantly improving early detection and survival of the disease. The work of the AllCaN Oesophageal network is led by Prof. Jacintha O'Sullivan (Trinity St. James's Cancer Institute) and co-led by Prof. Helen Coleman (Queen's University

Belfast) and Prof. Juliette Hussey (Trinity St. James's Cancer Institute). This unique cross-border collaboration links six major academic institutions across the island of Ireland (Trinity College Dublin, Queen's University Belfast, University College Cork, Royal College of Surgeons in Ireland, University College Dublin, and University of Galway – along with their associated hospitals, the National Cancer Control Programme, the Belfast HSC Trust and Industry partners) and will enable for the first time the bringing together of information from the Northern Ireland and Republic of Ireland Barrett's oesophagus registries (over 34,000 patients) to answer important epidemiological questions using one of the largest platforms available worldwide for studying this disease. Both a training network for early career researchers and PPI Panel will also form integral parts of the AllCaN network. More information on the AllCaN network and highlights from the launch can be found at [First All-Ireland Cancer Network launched - BBC News](https://www.bbc.com/news/health-58111111) and <https://www.youtube.com/watch?v=YoYswYU0T4Q>

Current funding: [Cancer Research UK](#) (N.Ireland Barrett's Register update), [Breakthrough Cancer \(AllCaN network\)](#) ;  
Historic funding sources: Medical Research Council, the HSC R&D Office Northern Ireland and [Cancer Focus NI](#)

### ***NI Colorectal polyp***

This Register includes information on all colorectal polyp diagnoses since 2000 in NI. The data from 2000-2005 and matched to cancer/death outcomes has previously been analysed to investigate the risk of cancer in relation to type of polyps, and findings show that elevated cancer risk remains in patients who have undergone polypectomy in this timeframe. This database was also used as a sampling frame for an NI Biobank-facilitated joint molecular epidemiology study with Vanderbilt University, TN, USA, to identify biomarkers for advanced recurrent adenomas.

The 2000-2005 database has also formed the basis of new analysis by PhD student Olivia Adair, supervised by Dr Felicity Lamrock, Professor Mark Lawler and Dr Ethna McFerran. Olivia will be applying mathematical modelling to determine the distribution of adenoma detection and rates of progression to cancer by different age groups.

### ***Bowel Cancer Screening***

Substantive progress has been made on colorectal polyp research in recent times thanks to the strengthening of links between the NICR team and the NI Bowel Cancer Screening programme (BCSP) pathology database, with analysis undertaken by postdoctoral research fellow Dr Ray Carragher under the leadership of Professor Maurice Loughrey and NICR Deputy Director Professor Helen Coleman. This one-year project was funded by the Belfast Health and Social Care Trust Charitable Funds, in collaboration with the relevant stakeholders of the BCSP.

Summarising the first ten years of pathology reporting from the Northern Ireland BCSP, this paper was published in *Histopathology* in 2023. Key findings include:

- More than 1,000 cancers have been detected through screening, the majority at an early stage
- Ten year trends show a steady decline in the proportion of index colonoscopies that yield a diagnosis of cancer, a measure of programme success
- A further 8,000 individuals have benefitted from having a colorectal adenoma, or other cancer precursor polyp, detected and removed as part of the BCSP
- Sessile serrated lesions are being detected more commonly than hyperplastic polyps by Year 10 of the BCSP

*Reference: Trends in pathology diagnoses over ten years of a colorectal cancer screening programme. Ray Carragher, Grace R Ings, Gavin Baker, Jeni Rosborough, Dorothy B. Johnston, Rajeev Shah, Iain Cameron, Ciaran O'Neill, Paul J Kelly, Gerard McVeigh, Steve Irwin, Kourosh Khosraviani, William Dickey, Tracy A Owen, Christine F McKee, Helen G Coleman, Maurice B Loughrey (Histopathology 2023; 83(5):756-770).*

A further research analysis, based on variations in pathology reporting by volume of samples reported is also underway and will form a chapter of a MD thesis by surgical registrar Miss Dorothy Johnston, who is supervised by Profs Coleman and Loughrey.

Historic funding sources: Belfast HSC Trust Charitable Funds; [Cancer Focus NI](#)

### ***Endometrial Hyperplasia (EH)***

Endometrial cancer is the most commonly diagnosed gynaecological cancer in developed countries and is the 4th most common cancer in UK women. Endometrial cancer rates are increasing in the UK, however there is currently no routine screening for endometrial cancer. Endometrial hyperplasia is a recognised precursor to endometrial cancer, which if detected, can help to prevent malignant progression. Little is known on the population incidence of endometrial hyperplasia, or which patients are most at risk of progressing to endometrial cancer. The Northern Ireland Endometrial Hyperplasia Register is being developed within the Northern Ireland Cancer Registry (NICR), which will be the first of its kind in the UK. This research is currently funded by a UKRI Fellowship awarded to Dr Úna McMenamín.

The Register consists of approximately 3,000 incident endometrial hyperplasia cases diagnosed from 2008-2022, identified from review of endometrial biopsy pathology reports. The Register is currently being used to investigate trends in diagnoses of endometrial hyperplasia, and progression to endometrial cancer, while planned linkage to external datasets will facilitate research into the evaluation of non-surgical, fertility-sparing therapies on future cancer risk and reproductive outcomes in endometrial hyperplasia patients. The Register has been used to evaluate the impact of the COVID-19 pandemic on diagnosis of endometrial hyperplasia as well as endometrial cancer in Northern Ireland<sup>5</sup> showing that in the first ten months of the pandemic (March and September 2020), there was a 42.9% reduction in the diagnoses of endometrial hyperplasia compared to the same time period in 2017-2019. For endometrial cancer, a 19% reduction in diagnoses was observed compared to the same time period in 2017-2019. Although endometrial cancer diagnoses showed signs of recovery, endometrial hyperplasia diagnosis continued to lag behind expected rates, likely because of the reprioritization of gynaecologic services due to the COVID-19 pandemic.

PhD student Chloe McCoy is currently using the NI Endometrial Hyperplasia Register linked to data from the NI Cancer Registry to conduct two population-based studies. The first study found that among women diagnosed with endometrial cancer in Northern Ireland, a total of 3% had a prior diagnosis of endometrial hyperplasia. A prior diagnosis of endometrial hyperplasia was associated with improved survival outcomes compared to those without a prior diagnosis, but this survival benefit was attenuated following additional adjustments for factors such as younger patient age, earlier cancer stage at diagnosis and tumour grade. This is the first population-based study to quantify the proportion of endometrial cancer patients with a prior diagnosis of endometrial hyperplasia and the draft article will shortly be submitted to a journal for publication. The second study is currently ongoing and aims to determine the proportion of 'missed' endometrial cancers following a diagnosis of endometrial hyperplasia and identification of patient demographic and clinical risk factors which may contribute to these missed cases. Chloe presented some of her research at the Cancer Research UK Early Detection of Cancer Conference in London in October 2023.

Importantly, these research studies include clinical input from local gynaecologists and gynaecological pathologists, as well as Public and Patient Involvement (PPI) from two patients affected by endometrial hyperplasia. Taken together, this research will generate robust population-level evidence to inform diagnostic, treatment, and surveillance strategies for women with endometrial hyperplasia with the ultimate aim of better informing clinical decision-making between women and their health care professionals.

Current funding: [UKRI Future Leaders Fellowship](#), Northern Ireland [Department for the Economy PhD studentship](#); Historic funding sources: [Queen's University Belfast International PhD Studentship](#) (this register builds on previous work led by Professor Helen Coleman).

### ***MGUS (Monoclonal Gammopathy of Undetermined Significance)***

This pre-malignant blood disorder commonly precedes multiple myeloma. This population-based database which is under construction will facilitate surveillance and assessment of the impact of MGUS on patient outcomes, such as rate of progression to cancer and subsequent survival.

Historic funding source: [Cancer Research UK](#) / [Northern Ireland Department for the Economy PhD studentship](#)



### ***NI Premalignant Cervical Lesions Register***

The Northern Ireland Premalignant Cervical Lesions Register (NIPCLR) was established in 2020. The aim is to construct a database containing information about all histologically verified high grade premalignant (in situ) cervical lesions diagnosed in Northern Ireland. This resource can be used to monitor incidence and prevalence, improve understanding of the diagnosis, treatment and progression of these lesions, evaluate the impact of screening and vaccination programmes and the effect of the coronavirus pandemic on the provision of services.

Work has included: standardising methods of data collection; reviewing the feasibility of deriving resection depth information from pathology reports; and starting the routine collection of CIN2 data. This pilot register has also been used as a basis for a PhD thesis chapter.

Due to the lack of regular funding, work on this project stopped in May 2022. Despite this, much of the data will continue to be collected through the core work of the main registry, and the NICR team will consider how to further enhance this pilot work and identify possible sources for further funding. With forthcoming changes to the range of premalignant lesions that are registrable, and potentially greater flexibility in the fields which can be collected with CENTRIS, it may mean that a separate premalignant register is no longer necessary to fulfil the aims.

We are very grateful to the Lynsey Courtney Foundation for their generous donations which have allowed the work to date.

Current funding: No current source of funding

*CIN = cervical intraepithelial neoplasia (grades 1-3)*

### **MEASURES OF DATA QUALITY**

NICR data quality are compared to England, Scotland, Wales and Ireland via the UKIACR Performance Indicators which have shown NICR data quality to be of a high standard. For example

- NI has the highest proportion of cancers staged (above 80%) from 2015 onwards ([see Appendix C](#)).
- NI has a low percentage of death certificate only registrations (which account for 1% of invasive malignancies registered, excluding NMSC)
- NI has a high percentage of microscopically verified cases (which account for 83.5% of invasive malignancies registered, excluding NMSC).

Data from NICR have been included in multiple international comparative studies and these organisations having to undertake minimal data cleaning due to the quality of NICR data:

- [ICBP](#)
- [EUROCARE](#)
- [Benchista](#)
- [Cancer Incidence in Five Continents](#),
- [Concord International Cancer Survival Studies](#),


### 3. REGISTRY IT SYSTEM

#### 3.1 Background

NICR are currently updating a legacy cancer registration database system (PRAXIS) which was developed in the 1990's. The PRAXIS system has many benefits, such as automated data linkage routines, which have not been fully replicated in other more recent systems. However, the underlying architecture is difficult to develop further, and the system is currently unsupported.

Consequently, we are currently working with a local IT company (CODEC) who successfully tendered to replace PRAXIS with a system that is more easily supported and developed. It will be a Cloud based solution, using newer technologies such as MS Dynamics and Power BI, and will have the ability to record information on disease progression.

#### 3.2 Method of Data Processing





- **Pathology Labs** – Pathology notifications/reports on new neoplasms
- **Cancer deaths** Notifications from the General Records Office (GRO)
- **BSO** – Demographic details and Prescription data
- **Multi-Disciplinary Team** extracts from Cancer Patient Pathway System (CaPPS)
- **Oncology and radiotherapy data** extractions from Regional Information System for Oncology & Haematology (RISOH) and Radiotherapy software ARIA
- **Surgical data** from Patient Administrative System (PAS)
- **Screening data** from PHA Screening Team.

- Cancer Intelligence Officers (CIOs) quality verify all notifications processed by data loading into UKIACR standard cancer registrations **by viewing Radiology Systems, CaPPS, RISOH and Labcentre**
- In instances where viewing these systems do not provide enough high-quality information the CIO team aim to review **patient paper notes**.

- Cancer registrations are formatted into **NICR Official Statistics**, outputs include;
- Publishing reports on cancer incidence, prevalence, survival and cancer trends
  - Routes to Diagnosis
  - Information for research
  - Audit Reports monitoring changes in cancer care
  - Information for HSC planning and service delivery
  - Assisting Genetics Counselling Services.

## 4. REGISTRY OUTPUTS

### 4.1 Official Statistics

NICR produces official statistics for incidence, prevalence, mortality and survival of cancer in NI. Official Statistics for 2021 cancer registrations were published in two phases, with statistics on lung, breast, colorectal, upper gastrointestinal cancer and melanoma published in October 2023, and data on the remaining cancer types published in May 2024. Statistics for 42 cancer types (including all cancers, and NMSC) are included as part of these releases and are available via the [NICR website](#).

Key characteristics presented for each cancer type include incidence trends and breakdowns of incident cases by patient demographics (e.g. sex and age), geographical areas (e.g. Health and Social Care Trust, Local Government District and Parliamentary Constituency), socio-economic deprivation and tumour characteristics (e.g. stage). Survival and prevalence statistics by key characteristics are included alongside the latest statistics on cancer mortality, with death data provided by the General Register Office Northern Ireland (GRONI).

Specific COVID impact reports for each cancer type were released alongside the annual official statistics comparing incidence, survival and mortality in 2021 with that of 2018-2019 and 2020, providing a novel and rapid assessment of the impact of COVID-19 on cancer patients and their care in NI.

## **4.2 Routes to Diagnosis**

In March 2022 the Department of Health launched a new Cancer Strategy for Northern Ireland<sup>1</sup> which set the direction for cancer services for the 10 years between 2022 and 2032. Action 5 of this strategy aims to - ***Establish routes to diagnosis reporting and analysis on a regular basis to monitor changes to help improve diagnostic s and outcomes for patients***

In 2023 the Northern Ireland Cancer Registry (NICR) was funded by the Department of Health to develop a routes to diagnosis project with the aim of providing an indication of the key event in each cancer patient's pathway that most directly led to their cancer diagnosis. Initially piloted in Northern Ireland in 2020 using data from 2012-2016<sup>2</sup>, which was in turn based upon a project which has been running in England since 2012<sup>3,4</sup>, this exercise classifies every case of cancer registered in NI as having one of the following eight Routes to Diagnosis.

The data required to assign this classification comes from several sources. The core data on cancer patients diagnosed from 2018-2020 is collected by the Northern Ireland Cancer Registry. This data is linked to hospital episode data (both inpatient and outpatient) from the Patient Administration System (PAS), referral data from the Cancer Patient Pathway System (CaPPS) and data supplied by the three cancer screening programmes in NI (bowel, breast and cervix).

The translation of this wealth of data into a single route to diagnosis is based upon the algorithm developed by the National Cancer Registration and Analysis Service in England<sup>3,4</sup>. This process works by initially assigning an endpoint based upon the hospital episode that occurred closest to diagnosis, and then working backwards to the event most likely to be the main referral source with certain key events, such as screening, given priority over others.

The first Routes to Diagnosis report was published in June 2024 and is available [here](#).

## **4.3 Cancer Factsheets**

There are 42 factsheets updated annually as part of the official statistics release. These are available on our [website](#).

## **4.4 Research Publications**

Since April 2023, 9 peer reviewed publications using NICR data have been produced (156 since January 2013) ([Appendix D](#)) which includes published acknowledgments of NICR data in conference abstracts and posters. Most recent NICR scientific articles have a lay summary sheet, available [here](#).

## **4.5 Information Requests**

NICR handle two main types of information request: general and genetic requests.

General requests cover a broad range, from descriptive statistical information to more complex analysis such as investigation of alleged cancer clusters. During 2023, all 64 general requests for information were completed within the 20 working days target.

Genetic requests largely come from Genetic Counselling Services across the UK and Ireland, but requests are also received from services worldwide. Release of data is guided by UKIACR policy which requires a named registered medical practitioner to be responsible for the confidentiality, use and security of the data. Consent must be received by NICR before data are released. The target for genetic requests is response within 10 working days and in 2023 the NICR completed all 104 genetic information requests received from outside NI within this timeframe ([Appendix E](#)). Within NI, the Clinical Genetic Service has a designated member of staff who manages these requests using special status access to NICR datasets for cancer genetics patients.

## 4.6 Reports

NICR has produced 43 reports covering survival, cancer incidence and survival trends, All-Ireland statistics and an All-Ireland Cancer Atlas with colleagues in the National Cancer Registry of Ireland (see [here](#)). The NICR also produces clinical audit reports (see [here](#)), with the most recent being an audit of [Pancreatic Cancer](#).

## 4.7 Other Uses of Registry Data

- Regular feedback of cancer cases to regional cancer screening services for quality assurance and improvement,
- Annual updates for Cancer Research UK to populate UK wide cancer statistics concerning cancer incidence, mortality, survival and risk factor data on their [webpage](#),
- Provision of data for national/international projects
  - a. International Cancer Benchmarking Partnership (ICBP) International Cancer Survival Phase 1 and 2 (see [here](#)),
  - b. Cancer Incidence in Five Continents (see [here](#)),
  - c. EUROCARE (see [here](#)),
  - d. European Cancer Information System (ECIS) (see [here](#)),
  - e. UK Cancer Survival Project-London School of Hygiene and Tropical Medicine (see [here](#)),
  - f. National Cancer Dataset Repository, Local Cancer Intelligence Commissioning Tool,
  - g. Northern Ireland Neighbourhood Information Service ([NINIS](#)),
  - h. CONCORD, (see [here](#)),
  - i. Benchista, (see [here](#)).
- Provision of timely data on the impact of COVID-19 on cancer services (see [here](#)),
- Health and Social Care Inequalities Monitoring System (HSCIMS) (see [here](#)).

## 4.8 Research Projects

### ***Research supervised by NICR staff***

- Dr Damien Bennett and Helen Mitchell have been supervising a BSc student Cherry Stevenson, who is helping investigate cancer patients admitted to hospital with COVID-19 from March 2020-Dec 2021. This work will be compared against cancer patients admitted to hospital without COVID-19 and will examine factors such as age, length of stay and method of admission.

### ***Projects facilitated within NICR by external researchers 2023-2024***

- Pre-existing Dementia or Stroke associated with Less Treatment and Poorer Survival in UK Cancer Patients – Findings from a Population-Based Study,
- An evaluation of the proportion of endometrial cancer patients with a prior diagnosis of endometrial hyperplasia and its influence on survival outcomes: a population-based study,
- Understanding the molecular age of Barrett's oesophagus in a population-representative sample of patients,
- Molecular biomarkers to predict progression of Barrett's Oesophagus (BO) to Oesophageal Adenocarcinoma (OAC),
- Smouldering Multiple Myeloma: Validation of a Detection Algorithm in a Northern Ireland Dataset and Impact on National Statistics,

- Trends in incidence and survival of head and neck cancer patients in Northern Ireland by demographic factors & COVID-19 impact,
- The Role of Infectious Agents in Progression from Barrett’s Oesophagus to Oesophageal Adenocarcinoma,
- Performing an emulated clinical trial in observational audit data to test prostate cancer patient interventions - a feasibility study.
- Exploratory Investigation of the Epidemiology and Inequalities in Time to Treatment of Paediatric Cancer in Northern Ireland
- Oesophageal Columnar Metaplasia in Childhood: A Population-Based Case Series Analysis
- Identifying characteristics of asymptomatic oesophageal cancer and Barrett’s oesophagus patients to inform novel prevention and early detection opportunities,
- Progression of adenomas within Northern Ireland,
- Mapping of Childhood Cancer rates in Northern Ireland,
- Investigating geospatial risk factors of cancer.

#### **4.9 Audits**

The Registry has previously completed a range of clinical audits evaluating the pathway of cancer patients to cancer services since 1996. 22 reports have been produced to date, making recommendations for service improvement with each report available on the [NICR website](#). Highlighting audit findings has provided media opportunities which allowed cancer prevention promotion and messaging around early cancer detection as well as raising the profile of NICR and QUB.

The most recent audits include:

1. Audit of Pancreatic cancer – funded by NI PANC – published in Spring 2023,
2. Audit of Breast Cancer COVID-19 Impact – funded by Breast Cancer Now – Data collection ongoing, report due Spring 2025
3. Research audit of Secondary Breast Cancer – funded by Cancer Focus NI – currently in phase 2 of a 3 phase project.

## **5. ISSUES OF CONCERN AND CHALLENGES FOR NICR**

Some of the challenges that the NICR faces over the coming years are outlined below:

### **5.1 Lack of a Legislative Framework for Disease Registration**

We are awaiting a legislative framework for cancer registration in NI. In April 2016, a Bill on Secondary Use of Health and Social Care Data received Royal Assent. This will require regulations to be drafted before consultation and final approval. The Minister of Health has been actively lobbied on this matter and this has been raised in the Cancer Strategy. Although NICR welcomes the legislation, there should be exemption for opt out from cancer registration similar to that in England. From a cancer registration perspective, a useful reference is from England where exemption from Type 2 objections was provided by Ministerial direction in 2016 for data required for cancer registration data as applied to the National Cancer Registration Service (NCRAS). Our concern is that offering a single, blanket opt-out for patients for all their healthcare data (e.g., via Encompass etc) may mean a significant drop in cancer cases and cancer data being available for cancer registration, which will make trend analysis and comparisons inaccurate and accurate investigation of cancer clusters impossible. Cancer registration depends on complete, continuous and consistent data on all cancer patients.

### **5.2 Access to Data Sources**

#### Access

Cancer registration depends on a continuous and consistent supply of data from a variety of sources to ensure complete and accurate recording of cancers in NI. When RISOH replaced COIS, it took four years to receive oncology treatment data. NICR now receives monthly downloads of SACT, however, despite appropriate governance being in place, NICR is still awaiting Read-Only access to RISOH to facilitate confirmation of diagnosis and obtain essential data on treatment needed for staging. Going forward, we are concerned the move to Encompass will lead to similar problems with securing access to data required for cancer registration. Disruption to existing data flows mean delays or gaps in cancer registration, which undermines confidence in data and outputs.

#### Minimum Cancer Dataset (MCD) for Registration

Currently, unlike in England, there is no mandated minimum cancer dataset (COSD – Cancer Outcomes Services Dataset) required from Trusts in NI. The development of a minimum dataset was a recommendation from the recent Cancer Strategy and the latest NICR peer review. COSD is used by the cancer registry in England (NCRAS) to provide much of the data items required for national audit. Adopting a similar approach in NI would help facilitate timely audit and allow for benchmarking with other regions. Although it may be possible to embed these fields within Encompass, this has not yet been agreed. The development of a NI level MCD will require input from NICR staff.

### **5.3 IT System**

NICR are currently replacing its legacy registration database system (PRAXIS), which has been in operation for 20 years. The replacement system will have the capacity to record additional data such as disease progression and molecular markers and will allow enhanced reporting. It is hoped that additional funding will allow further enhancements such as integration of the cancer staging tool, inclusion of key performance indicators required for local/national audit and extension to premalignant registers.

### Recording of disease progression

Recording of disease progression (including recurrences, secondary and metastatic cancers), will require development of the IT system, as described above. However, this will not mean NICR staff will begin recording disease progression as NICR is funded to record primary disease only. Substantial additional staff would be required to record disease progression. Recruitment and training of these staff would also take some time. A Secondary Breast Cancer Research Audit funded by Cancer Focus should allow NICR to assess some of the practical issues associated with the process.

### **5.4 Annual Funding**

NICR is currently funded by the PHA, but the University considers this an annual grant. There are still difficulties in staff retention and recruitment as posts can only be advertised on a short-term basis, usually one year. Therefore after 6 months staff are receiving end of contract notifications and being offered other posts in the university via QUB redeployment portal. Long term planning is required to attract and retain staff.

### **5.5 Funding for Audits**

Audits provide a mechanism to benchmark local services against best practice guidelines and also with providers outside NI. It requires comparison of patient level datasets using similar methodologies and the rigorous collection of datasets. There is strong support across a range of stakeholders (cancer clinicians, NiCaN, PHA, SPPG etc) for better audit data. The NICR 2018 Peer Review made recommendations about exploring how NICR can support Clinical Audits. The NICR has a strong record of undertaking local audit since 1996 and to date has published 21 audits. However, funding for each audit comes from various external sources such as RQIA, GAIN and charities. For example, the recent audit of pancreatic cancer was funded by NIPANC, whilst research on breast cancer diagnoses, treatment and outcomes pre and post COVID-19 have been funded by Breast Cancer Now. Audits of colorectal cancer and oesophageal cancer were funded on an ad hoc basis by the PHA/RQIA/OG Cancer NI. Regular funding is required to allow an ongoing cycle of regular audits by experienced NICR staff, which will retain staff skilled in data collection and analysis.

### **5.6 Staffing and Succession Planning**

NICR has a relatively small team of highly specialised staff, often with long experience. Although staff turnover is low and staff are very committed, there are risks as staff retire or leave for other posts. Recruitment and retention of IT staff has been problematic, with currently only a single IT officer in post. Additional resources to allow work shadowing and training of new staff would reduce the risk of skills and expertise loss in this small group. The post of Director has been filled however this is only on an interim basis and a permanent appointment should be made.

#### *\* Amendment as of August 2024\**

Following discussions in July/August 2024, the PHA and QUB arranged that the Interim Director's post would transition from its current secondment status to a permanent QUB position, but unfortunately this would be with Dr Damien Bennett only covering 80% of the role (with 20% in PHA). The Director's post remains a full-time position and the 20% of the role will have to be covered by another individual.



## 6. NICR RESOURCES

### 6.1 Current staff and funding

NICR is currently funded (as a population-based cancer registry) by the PHA, with the University considering this an annual grant. Budget for 2022-2023 was £913,293, with over 90% spent on salaries. The Registry submits research and audit applications to various funding bodies and, if successful, undertake specific research/audit projects. The budget allocation for 2023-2024 is £945,633.




Figure 3: Current PHA/Grant funded staff 2023-2024

FTE = Full Time Equivalent

Colour code; Blue = PHA, Green = Grant/Additional funding, Amber = CPH

Regarding figure 3:

- NI Biobank currently fund 1 FTE CIO,
- Breast Cancer Now fund a 2-year COVID impact audit for 2018 & 2020 – 2x 0.5FTE CIOs, 1FTE Analyst,
- Heart Research UK fund 1 FTE Researcher until Spring 2024
- Routes to Diagnosis funded by PHA fund 1FTE Researcher

Due to continued increase in the number of cancers and their complexity, NICR will require additional data verification and analytical support and a more sustainable model of funding (see Figure 1 on page 9).

In the area of clinical audit, an audit team could be developed to work on a rolling cycle with the major tumour sites audited at least every five years with comparisons in national audits.

## 6.2 Allocations from PHA

Table 1: Allocation from PHA

Funding from Health Agency	Public	Funding 2019/2020	Funding 2020/2021	Funding 2021/2022	Funding 2022/2023	Funding 2023/2024
Total Core Work		£844,973	£861,444	£878,673	£913,293	£945,633
Routes to Diagnosis						£77,967
International Benchmarking Partnership	Cancer					£15,450

Funding for 2024-2025 is not yet confirmed.

## 6.3 Other funding

In addition to the allocation from PHA, NICR has gained support for other research projects including; Heart Research UK, two audit projects, Breast and Pancreatic (funded by Breast Cancer Now and NI Panc). Cancer Focus has also recently agreed to support a Secondary Breast Cancer Research Audit (Table 2).

Table 2: Research/Audit Expenditure relating to projects active during the period 1 April 2016 – 31 March 2023

	Funder	Start Date	End Date	Total Budget	Expenditure up to 31/03/23	Balance c/f 2023-2024
Cardiovascular Disease	Heart Research UK	01/01/20	31/12/24	£149,991	£149,991	£0
Breast COVID-19 Audit	Cancer Impact Breast Cancer Now	01/05/22	30/04/24	£229,126	£74,851	£154,275
Secondary Cancer Audit	Breast Research Cancer Focus	01/04/23	31/03/25	£60,000	£30,000	£30,000

## Update on Actions for 2023-2024

**Table 3: Update on Key Priorities 2023-2024**

Colour code: Green = completed, Amber = ongoing, Red = not completed

Targets 2023/2024	Update
1. Provide complete, accurate data on cancers in NI for official statistics by March 2024 for patients diagnosed in 2021	- Produced for 6 sites ie, - Lung cancer - Bowel cancer - Breast cancer and insitu tumours - Oesophageal cancer - Stomach cancer - Malignant melanoma - Estimated completion for all sites May 2024
2. Develop Routes to Diagnosis data and outputs	- Initial draft produced, publication June 2024
3. Respond to general data and information requests within a timely manner	- 61 out of 64 General requests responded to within 20/day target - Development begun on electronic Request Monitoring Service
4. Respond to requests from the family genetic services within a timely manner	- All 104 Genetic requests responded to within 10-day target - Development begun on electronic Request Monitoring Service
5. Provide NI datasets for international comparisons and collaborations e.g., ICBP, Eurocare, Concord, ENCR	- Ongoing contributions to ICBP phase 3 - Submitted to CONCORD
6. Seek to acquire clinical information on oncology patients by acquiring full read-only RISOH access as per Trust agreements	- Ongoing
7. Seek to ensure NICR requirements are met by future HSC systems e.g., Encompass/LIMS	- ENCOMPASS – Information Governance Advisory Council Meeting attended 13 <sup>th</sup> March, seeking to engage with SE Trust for future engagement - Good communication with LIMS teams re requirements and roll out
8. Maintain ISO27001 Certification in Information Security Management	- Recertified May 2023. - Work ongoing to prepare for new standard
9. Implement new Registry IT System and ensure it is fully operational for staff	- Delayed due to change in project management - Working towards system completion
10. Enhance and improve NICR data outputs and seek to tailor for individual stakeholders	- Data supplied to NICaN, SPPG and DOH - Engaged with CPH stakeholders, - Meetings with DOH, SPPG and Charity sector representatives - Data analytics member of staff in place
11. Provide data for UKIACR annual Performance Indicators	- Completed with NI having the highest level of stage in the UK & Ireland see <a href="#">here</a>

Targets 2023/2024	Update
12. Provide data on the impact of COVID-19 on cancer services	- Completed – see <a href="#">here</a>
13. Continue to work with external researchers to enhance cancer research in NI	- CPH researchers, - DOH researchers, - Attendance & poster/oral presentations at conferences, ie; ENCR/IACR, Benchista, European Health Dublin, RCSI Dublin - Royal College of Surgeons London Pancreatic Cancer event, - PHA Regional Interval Breast Cancer Day
14. Ensure Standard Operating Procedures are kept up to date	- On-going
15. Ensure NICR Director Post is secured on permanent basis	- Ongoing – raised at Quarterly Steering Group meetings and Bi-Annual Council meetings
16. Undertake a formal data quality assessment of the NICR data	- Ad hoc data quality completed – need to identify data quality assurance post funding
17. Secure funding for ongoing collection of data on premalignant diseases	- AllCaN network for Barrett’s Oesophagus established, - Endometrial Hyperplasia continues
18. Secure resources needed to collect additional NICR data items as per ENCR guidance and recommendations (e.g., treatment, comorbidities, tumour markers, recurrences [pending])	- Not completed
19. Secure resources to allow collection of CIN II and NMSC data in line with UKIACR counterparts and ENCR recommendations	- Raised at NICR Steering Group meeting – no progress made
20. Work with local charities, clinicians, RQIA, NICaN and PHA to secure funding to undertake audits	- Ongoing
21. Investigate development of rapid datasets (RDs)	- On-going – funding required
22. Increase awareness of the opportunities NICR data can provide	- On-going – Attendance at conferences and meetings to present NICR outputs

## NICR Key Priorities 2024-2025

1. Provide complete, accurate data on cancers in NI for official statistics by March 2025 for patients diagnosed in 2022,
2. Respond to general data and information requests within a timely manner,
3. Respond to requests from the family genetic services within a timely manner,
4. Develop Routes to Diagnosis data and outputs,
5. Provide NI datasets for international comparisons and collaborations e.g., ICBP, Eurocare, Concord, ENCR,
6. Enhance display and usability of NICR data outputs and seek to tailor for individual stakeholders,
7. Seek to acquire clinical information on oncology patients by acquiring full read-only RISOH access as per Trust agreements,
8. Seek to obtain relevant information from ENCOMPASS and secure ongoing data abstracts,
9. Maintain ISO27001 Certification in Information Security Management,
10. Implement new Registry IT System and ensure it is fully operational for staff,
11. Explore opportunities with new and existing NICR resources, e.g. treatment, comorbidities, recurrences, rapid datasets,
12. Provide data for UKIACR annual Performance Indicators,
13. Provide data on the impact of COVID-19 on cancer services,
14. Continue to work with external researchers to enhance cancer research in NI,
15. Ensure Standard Operating Procedures are kept up to date,
16. Ensure NICR Director Post is secured on permanent basis,
17. Undertake a formal data quality assessment of the NICR data,
18. Secure funding for ongoing collection of data on premalignant diseases,
19. Explore resources needed to collect additional NICR data items as per ENCR recommendations (e.g., comorbidities, tumour markers, recurrences),
20. Secure resources to allow collection of CIN II and NMSC data in line with UKIACR counterparts and ENCR recommendations,
21. Work with clinicians, RQIA, NICaN, local charities and PHA to secure funding to undertake audits,
22. Investigate development of rapid datasets (RDs) – using CAPPs and SACT data,
23. Increase awareness of the opportunities NICR data can provide,
24. Expand on secondary cancer research audit,
25. Expand on current breast cancer inequalities work to other sites,
26. Link with Biobank,
27. Explore N/S Research projects,
28. Explore further use of co-morbidity data
29. Ensure transfer from PAS to ENCOMASS,
30. Implement new NICR Branding,
31. 30th Anniversary Celebration.

Although the Registry will continue to seek additional resources from external sources, a more sustainable model of funding for NICR is required to ensure it continues to provide a cancer intelligence service with high quality, timely, accurate data for service planning and evaluation, research and education.

**Table 4: NICR Key Priorities 2024-2025**

Targets 2024/2025	Proposed Actions
1. Provide complete, accurate data on cancers in NI for official statistics by March 2025 for patients diagnosed in 2022	<ul style="list-style-type: none"> <li>- Release Official Statistics by March 2025</li> </ul>
2. Respond to general data and information requests within a timely manner	<ul style="list-style-type: none"> <li>- Develop an electronic Request Monitoring Service to provide better tracking of requests, status and timeliness</li> </ul>
3. Respond to requests from the family genetic services within a timely manner	<ul style="list-style-type: none"> <li>- Monitor timeliness of responses to genetic requests</li> </ul>
4. Develop Routes to Diagnosis data and outputs	<ul style="list-style-type: none"> <li>- Produce Routes to Diagnosis data for 2021</li> </ul>
5. Provide NI datasets for international comparisons and collaborations e.g., ICBP, Eurocare, Concord, ENCR	<ul style="list-style-type: none"> <li>- Datasets to be submitted by agreed dates</li> </ul>
6. Enhance display and usability of NICR data outputs and seek to tailor for individual stakeholders	<ul style="list-style-type: none"> <li>- Review how other registries and data providers present and use data</li> <li>- Develop using modern technologies better user interfaces for data accessibility</li> <li>- Engage with stakeholders/Steering Group to establish user needs and acceptability</li> </ul>
7. Seek to acquire clinical information on oncology patients by acquiring full read-only RISOH access as per Trust agreements	<ul style="list-style-type: none"> <li>- Liaise with BSO to enable read-only RISOH access once BSO's upgrade for third party access is complete.</li> <li>- Continue to raise this issue at NICR Steering Group meetings</li> </ul>
8. Seek to obtain relevant information from ENCOMPASS and secure ongoing data extracts	<p>NICR staff will</p> <ul style="list-style-type: none"> <li>- Continue to attend Encompass Cancer Decision Group Meetings</li> <li>- Link with the new LIMS project management team</li> </ul>
9. Maintain ISO27001 Certification in Information Security Management	<ul style="list-style-type: none"> <li>- Undertake regular internal audits to ensure confidence with NICR ISO policies.</li> <li>- Liaise with QUADRA to implement new Standard.</li> </ul>
10. Implement new Registry IT System and ensure it is fully operational for staff	<ul style="list-style-type: none"> <li>- Undertake comprehensive User Acceptance Testing (UAT) of the new IT system with involvement of NICR staff from each work area.</li> <li>- Staff training</li> <li>- Complete data migration</li> <li>- Parallel testing of CENTRIS and PRAXIS</li> <li>- Investigate further enhancements in line with user requirements</li> <li>- Establish ongoing support for IT system (funding required)</li> </ul>
11. Explore opportunities with new and existing NICR resources, e.g. treatment, comorbidities, recurrences, rapid datasets	<ul style="list-style-type: none"> <li>- Prioritise area of work in line with stakeholders needs</li> <li>- Present opportunities and associated resources needed to funding bodies</li> </ul>

Targets 2024/2025	Proposed Actions
12. Provide data for UKIACR annual Performance Indicators	- Submit data to UKIACR either by due date or within one month of final release of Official Statistics
13. Provide data on the impact of COVID-19 on cancer services	- Reports to be released quarterly, with possibility of less frequent release on review
14. Continue to work with external researchers to enhance cancer research in NI	Provide researchers with: <ul style="list-style-type: none"> <li>- Datasets from NICR data sources</li> <li>- Secure environment for analysis of NICR data</li> <li>- Advice on data availability/opportunities</li> <li>- Advice and support with data interpretation outputs</li> </ul>
15. Ensure Standard Operating Procedures are kept up to date	- Undertake review of NICR SOPs as processes develops at least annually
16. Ensure NICR Director Post is secured on permanent basis	- Work with NICR Steering group, QUB and PHA to secure permanent post
17. Undertake a formal data quality assessment of the NICR data	- Set up schedule of data quality assessments with input from NICR staff across various workstreams
18. Secure funding for ongoing collection of data on premalignant diseases	- Work with CPH researchers to investigate potential funding sources to support continuity of premalignant registers
19. Explore resources needed to collect additional NICR data items as per ENCR recommendations (e.g., comorbidities, tumour markers, recurrences)	- Determine process for additional data item collection, quantify resources required and explore possible funding sources
20. Secure resources to allow collection of CIN II and NMSC data in line with UKIACR counterparts and ENCR recommendations	- Explore potential funding sources for additional data collection
21. Work with clinicians, RQIA, NICaN, local charities and PHA to secure funding to undertake audits	- Investigate potential funding sources to support regular ongoing clinical audits - Secure funding for Blood and Skin cancer audits
22. Investigate development of rapid datasets (RDs) – using CAPPs and SACT data	- Undertake exploratory QA exercise using existing NICR data sources in line with practice in other Registries - Scope development of rapid dataset for NI and investigate quality issues, including strengths and weaknesses
23. Increase awareness of the opportunities NICR data can provide	Membership of <ul style="list-style-type: none"> <li>- The Cancer Data Steering Group</li> <li>- Cancer Strategy Steering Group</li> <li>- CPH Cancer Epidemiology Research Group</li> <li>- Attendance at Clinical Reference Groups (CRGs)</li> <li>- Maintain media engagement (see <a href="#">Appendix F</a>)</li> <li>- Ensure new staff within stakeholder groups are invited to visit the NICR</li> </ul>
24. Expand on secondary cancer research audit	- Expand to other sites - Explore research funding proposals based on SBC work
25. Expand on current breast cancer inequalities work to other sites	- Explore if methodology can be applied to other sites - Explore research funding proposals based on this work
26. Link with Biobank	- Attend NI Biobank meetings
27. Explore N/S Research projects	- Submit proposal for All Island Atlas

Targets 2024/2025	Proposed Actions
<b>28.</b> Explore further use of co-morbidity data	- Explore funding to further exploit CVD dataset
<b>29.</b> Ensure transfer from PAS to ENCOMASS	- Involvement in archiving of TRUST data when ENCOMPASS transfer complete - Attendance at appropriate planning meetings
<b>30.</b> Develop new NICR Branding	- Liaise with QUB Media to develop new NICR logo and branding
<b>31.</b> 30 <sup>th</sup> Anniversary Celebration	- Event planned 4 <sup>th</sup> June in the Great Hall, QUB - Past & Current staff participate in presentations & panels - Display of 'History of the NICR'



## REFERENCES

1. A Cancer Strategy for Northern Ireland 2022-2032; Published March 2022, Department of Health for Northern Ireland. <https://www.health-ni.gov.uk/publications/cancer-strategy-northern-ireland-2022-2032>
2. Centre for Public Health. Pathways to a cancer diagnosis 2012-2016. Queen's University, Belfast 2020. <https://pure.qub.ac.uk/en/publications/pathways-to-a-cancer-diagnosis-monitoring-variation-in-the-patient>
3. Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets. Br J Cancer 2012; 107:1220-6. <https://pubmed.ncbi.nlm.nih.gov/22996611/>
4. Public Health England. Routes to diagnosis 2006-2016: Technical document. Accessed Jan 2024.
5. Wylie J, Quinn D, Donnelly DW, McCluggage WG, Coleman HG, Gavin A, McMenamin ÚC. [The impact of the COVID-19 pandemic on endometrial cancer and endometrial hyperplasia diagnoses: a population-based study](#). American Journal of Obstetrics & Gynaecology. 2021; 226:737-739.
6. Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, Bannon F, Hicks B, Kennedy G, Gavin AT, Murray LJ. [Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study](#). Gut 2015;64(1):20-5.
7. Coleman HG, Bhat SK, Murray LJ, McManus DT, O'Neill OM, Gavin AT, Johnston BT. [Symptoms and endoscopic features at Barrett's esophagus diagnosis: implications for neoplastic progression risk](#). Am J Gastroenterol 2014;109(4):527-34.
8. Bird-Lieberman EL, Dunn JM, Coleman HG, Lao-Sirieix P, Oukrif D, Moore CE, Varghese S, Johnston BT, Arthur K, McManus DT, Novelli MR, O'Donovan M, Cardwell CR, Lovat LB, Murray LJ, Fitzgerald RC. [Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus](#). Gastroenterology 2012;143(4):927-35.e3.
9. Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. [Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus](#). Gastroenterology 2012;142(2):233-40.
10. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ. [Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study](#). J Natl Cancer Inst 2011;103(13):1049-57. Erratum in: J Natl Cancer Inst. 2013;105(8):581.
11. Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. [Increasing incidence of Barrett's oesophagus: a population-based study](#). Eur J Epidemiol. 2011 Sep;26(9):739-45. doi: 10.1007/s10654-011-9596-z.
12. Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RG, McCarron P, Gavin AT. [Mortality in Barrett's oesophagus: results from a population based study](#). Gut 2003;52(8):1081-4.
13. Murphy SJ, Anderson LA, Mainie I, Fitzpatrick DA, Johnston BT, Watson RG, Gavin AT, Murray LJ. [Incidence of colorectal cancer in a population-based cohort of patients with Barrett's oesophagus](#). Scand J Gastroenterol 2005;40(12):1449-53. Erratum in: Scand J Gastroenterol 2006;41(2):247.

14. Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A. [Risk of adenocarcinoma in Barrett's oesophagus: population based study.](#) BMJ 2003;327(7414):534-5.
15. Coleman HG, Loughrey MB, Murray LJ, Johnston BT, Gavin A, Shrubsole MJ, Bhat SK, Allen PB, McConnell V, Cantwell MM. [Colorectal cancer risk following adenoma removal: a large prospective population-based cohort study.](#) Cancer Epidemiol Biomarkers Prev 2015; 24(9):1373-80.
16. Santin S, Murray L, Prue G, Gavin A, Gormley G, Donnelly M. [Self-reported psychosocial needs and health-related quality of life of colorectal cancer survivors.](#) European Journal of Oncology Nursing 2015; 19; 336-342.
17. McClements J, Fitzpatrick D, Campbell WF, Gavin A. [Changes in Management and outcome of patients with rectal cancer in Northern Ireland: 1996-2006.](#) Colorectal Disease 2014;16(2): O58-65.
18. Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, Maxwell R, Nedrebø B, Pahlman L, Sjövall A, Spigelman A, Engholm, Gavin A, Gjerstorff ML, Hatcher J, Johannesen TB, Morris E, McGahan CE, Tracey E, Turner D, Richards MA, Coleman MP & The ICBP Module 1 Working Group. [Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007.](#) Acta Oncol 2013;52(5):919-32.
19. Mitchell, H., Alford, B. S., O'Hare, S., O'Callaghan, E., Fox, C. & Gavin, A. T., [Impact of the COVID-19 pandemic on emergency hospital cancer admissions in a UK region](#) BMC Cancer. 22, Article number: 850 (2022)

## APPENDIX A: Steering Group, Council and Research Advisory Group Membership and Role

### NICR Steering Group

Role of Steering Group as revised 8<sup>th</sup> February 2012;

- a) Agreeing the Registry's strategic objectives,
- b) Providing specialist advice,
- c) Agreeing the Registry's development strategy and annual business plan,
- d) Being informed about registry performance and advising in setting priorities in improving or enhancing performance,
- e) Assisting the Registry in matters of general policy where these impact upon the wider mainstream activity of the NHS, in the Health and Social Services Boards, Health and Social Care Trusts, Provider Organisations and the NI Cancer Network.

The Steering Group meets quarterly.

Prof Mark Lawler (Chair)	Associate Pro-Vice-Chancellor and Professor of Digital Health Faculty of Medicine, Health and Life Sciences
Ms Jean Frizzell	HSC Board, Financial Accounts & Governance
Mr Richard Spratt	Cancer Focus NI, CEO
Dr Gareth Irwin	Health and Social Care Trust Clinician
Dr Louise Herron	Public Health Agency
Ms Louise Dunlop	QUB, Governance
Dr Emma Allott	QUB, PGJCCR

With attendance from Registry Director, Deputy Director and relevant staff required for the agenda.

### NICR Council

Role ***“to pursue the aims of the Registry and to identify and enhance opportunities for use of the Registry data”*** by advising the Director and Steering Group. Frequency of meetings - twice a year. It provides a mechanism to liaise with key stakeholders.

Mr Jim McGuigan (Chair)	Belfast HSC Trust
Dr Maurice Loughrey (Deputy Chair)	Pathologist Belfast HSC Trust
Ms Barbara Roulston	Cancer Research UK
Dr Brid Farrell	Public Health Agency
Ms Rosemary Rainey	Lay Representative
Dr Jacqueline James	Pathologist QUB and NI Biobank
Prof George Kernohan	Ulster University
Ms Davinia Lee	Belfast HSC Trust
Dr Claire Lewis	NI Biobank
Dr Seamus McAleer	Oncologist QUB
Ms Janice Preston	Macmillan NI
Dr David Morrison	Director of the Scottish Cancer Intelligence Service
Ms Debbie Keatley	Lay Representative
Dr Collette McCourt	Belfast HSC Trust, Dermatologist
Dr Deirdre Donnelly	Belfast HSC Trust

Dr Deirdre Murray	Director of the Irish Cancer Registry
Dr Gillian Rea	Genetics Services
Mr Gareth Kirk	Action Cancer
Dr Sarah McKenna	Belfast HSC Trust
Dr Michael Reilly	Western HSC Trust

With attendance from Registry Director, Deputy Director and relevant staff required for the agenda.

### **Research Advisory Group**

Role is to review Data Information requests received to the Registry to ensure they have a scientific rationale, appropriate methodological approach and are covered by the existing ethics approval held by the NICR. The Research Advisory Group join the bi-annual NICR Council Meetings with extraordinary meetings convened to review Data Information requests when required.

Prof Helen Coleman	QUB, CPH
Prof Ciaran O'Neill	QUB, CPH
Dr Edward Goodall	NI Cancer Research Forum
Ms Dorianne Finlay	NI CRUK & Marie Curie
Ms Ashley Hurst	NI Cancer Research Forum
Dr Cherith Semple	Ulster University
Dr Nicola Armstrong	PHA
Dr Aidan Cole	Health and Social Care Trust/QUB
Dr Charlene McShane	QUB, CPH
Dr Olinda Santin	QUB, School of Nursing Midwifery
Dr Emma Allott	QUB, PGJCCR
Dr Nick Orr	QUB, PGJCCR
Dr Chris Cardwell	QUB, CPH (Statistician)

## APPENDIX B: Patient Information Leaflet

### Do I have a choice?

Yes, you do have the right to opt-out and this will not affect the care you receive.

However, in order to work properly, the registration system needs to know about everyone with cancer.

Your details help care teams to learn how best to treat cancer, make sure they provide the best care and help to find out the causes of cancer.

If you are concerned about your details being registered or any other issues in this leaflet, please discuss this with your Doctor or contact the N. Ireland Cancer Registry directly Tel 028 9097 6440.

### Where can I get more information?

If you have any questions, you can get more information by contacting:

- N. Ireland Cancer Registry  
Telephone 028 9097 6440  
Visiting the cancer registration website at [www.qub.ac.uk/nicr](http://www.qub.ac.uk/nicr); the website has a useful section on common questions about the cancer registration system.
- Cancer Focus Northern Ireland  
Helpline 0800 783 3339  
9am - 1.00 pm, Monday to Friday

If you are a child with cancer or the parent of a child with cancer, you can get further information by visiting the Children's Cancer and Leukaemia Group's website at [www.cclg.org.uk](http://www.cclg.org.uk).

This leaflet was adapted for use in Northern Ireland from the NHS "About cancer registration" leaflet which received the following awards:



The text of this document may be reproduced without formal permission. This leaflet is also available at [www.qub.ac.uk/nicr](http://www.qub.ac.uk/nicr)

If you require further copies of this publication please contact the N. Ireland Cancer Registry:

Tel: 028 9097 6440  
Email: [nicr@qub.ac.uk](mailto:nicr@qub.ac.uk)



revised May 2018

### About Cancer Registration A leaflet for patients



### What is cancer registration?

When someone is diagnosed with cancer or a condition that might lead to cancer, the doctor or hospital records the relevant details about your care and treatment. This applies to people of all ages, including children.

This information is collected by the Northern Ireland Cancer Registry and we would like to make sure that patients know this is happening.

### Why is registration necessary?

Registration is the only way that we can see how many people are getting cancer and what types of cancer they have.

Most countries in the world have a registration system including England, Wales, Scotland and the Republic of Ireland. Registration has been running in Northern Ireland since 1993.

By working with cancer researchers, cancer registries have been able to identify the causes of some cancers. It also allows us to look at how cancer patients are treated and how successful treatments have been for different types of cancer. Registration also helps us to make sure cancer screening programmes are working. Registration shows whether the number of people getting cancer is going up or down, so the

health service can make sure services and staff are available in the right place.

The information registered is vital for research into cancer. Cancer registration is supported by all the main cancer charities. \*see below

### What do you need to know about me?

We need to know some details about you (such as your name, address, age and sex). We need these details to make sure we are recording the right information about the right person.

We also need to know about cancer related investigations such as screening tests and PSA tests, the treatment you are receiving or have already received and your progress. Other diseases for example heart disease may affect survival so we need also to know about other diseases so we can accurately account for survival differences.

We need this information to help us to identify possible causes of cancer and to find out about the best treatments.

### Do I need to do anything?

No, you do not need to do anything - there are no forms to fill in and nothing to sign. Your hospital or doctor will confidentially pass the relevant

information to the Northern Ireland Cancer Registry during your care.

### What will we do with this information?

We are very careful with the information and follow strict rules about how we look after it and who can use it.

Our information security systems are certified to ISO27001 which is an independently verified accreditation that ensures the information we collect is stored and processed with robust confidentiality and integrity for processes and procedures.



Reports that we publish will never identify any particular person, even if they have a rare cancer.

### Will anyone contact me?

The Registry works with researchers to improve understanding of cancer. Usually this is with information which would not identify a person. Occasionally for some studies a researcher may need to contact patients. This is done only under strict conditions and your consent would be sought through your doctor/hospital before this would happen.

\* Action Cancer, Against Breast Cancer, Bloodwise, Bowel & Cancer Research, Bowel Cancer UK, Brain Tumor Research, Brain Tumor Research Campaign, Braintrust, Breast Cancer Campaign, British Lung Foundation, Cancer Fund for Children, Children's Cancer Unit, Cancer Focus Northern Ireland, Core - the Digestive Disorders Foundation, Cancer52, Cancer Research UK, GIST Support UK, It's in the Bag, James Whale Fund for Kidney Cancer, Jo's Cervical Cancer Trust, Skoin - The Karen Clifford Skin Cancer Charity, Lymphoma Association, Macmillan Cancer Support, Marie Curie Cancer Care, Melanoma Focus, My Name is NOT Cancer, Myeloma UK, Pancreatic Cancer Action, Rarer Cancers Foundation, Sarcoma UK, Shine Cancer Support, Skin Cancer Research Fund, Target Ovarian Cancer, Teenage Cancer Trust, The Pelican Cancer Foundation, The Pink Ribbon Foundation, WMUK

## APPENDIX C: Performance Indicators for 2020

	Key	
	Target not reached or not in line with other registries	
	Target attained	
Indicator	Northern Ireland 2021 report on 2019 diagnoses	Northern Ireland 2022 report on 2020 diagnoses
<b>Stability:</b> Percentage change (%) for all cancers (C00-C97 ex. C44) compared with previous three years	3.3%	-8.0%
<b>Registry Creep:</b> Percentage (%) for all cancers (C00-C97 ex. C44) registrations (extracted between 31/12/19 and 20/04/2020) compared with registrations extracted between 02/02/2019 and 01/03/2019 <sup>6</sup> .	1.4%	1.0%
<b>Staging:</b> Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2018 registered cancers (C00-C97 ex. C44) <sup>2</sup>	82.0%	81.2%
<b>Average of Core Patient Information Complete:</b> Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information <sup>3</sup>	100.0%	99.9%
<b>Average of Core Tumour Information Complete:</b> Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information <sup>4</sup>	96.9%	96.3%
<b>Death Certificate Only (DCO) Rates:</b> Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO <sup>5</sup>	0.6%	0.9%
<b>Zero Day Survivors:</b> Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis <sup>5</sup>	0.6%	1.1%
<b>Microscopically Verified:</b> Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified	85.8%	83.4%
<b>Non-Specific Codes:</b> Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non-specific morphology codes	2.6%	1.2%
<b>Grade:</b> Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade	59.7%	59.6%
<b>Treatment:</b> Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment	84.5%	74.8%
<b>Cervical Screening Data:</b> Percentage of cervical cancer (C53) cases screen detected for ages 25-60	63.1%	61.3%

## **APPENDIX D: Peer reviewed publications**

### **NICR Publications April 2023 – March 2024**

- 1. Cost consequences of unscheduled emergency admissions in cancer patients in the last year of life**  
McFerran, E., Cairnduff, V., Elder, R., **Gavin, A.** & Lawler, M.,  
01 Mar 2023, In: Supportive Care in Cancer.  
<https://doi.org/10.1007/s00520-023-07633-6>
- 2. Whole-population trends in pathology-confirmed cancer incidence in Northern Ireland, Scotland and Wales during the SARS-CoV-2 pandemic: A retrospective observational study**  
Greene, G. J., Thomson, C. S., Donnelly, D., Chung, D., Bhatti, L., **Gavin, A. T.**, Lawler, M., Huws, D. W., Rolles, M. J., Bennée, F. & Morrison, D. S., Jun 2023, In: Cancer Epidemiology.  
<https://doi.org/10.1016/j.canep.2023.102367>
- 3. Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland**  
Mitchell, M, Mclean, J, Gavin, AT, Visser, O, Millar, E, Luff, T & Bennett, D., July 2023  
In: BMC Cancer  
<https://doi.org/10.1186/s12885-023-11216-3>
- 4. Cancer data quality and harmonization in Europe: the experience of the BENCHISTA Project - international benchmarking of childhood cancer survival by stage.**  
Lopez-Cortes A, Didonè F, Botta L, Hjalgrim LL, Jakab Z, Canete Nieto A, Stiller C, Zeller B, Gatta G, Pritchard-Jones K; BENCHISTA Project Working Group.  
Front Oncol. 2023 Aug 22;13:1232451. doi: 10.3389/fonc.2023.1232451. eCollection 2023.  
<https://doi.org/10.3389/fonc.2023.1232451>
- 5. Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: results from the NI-HEART study**  
Walls, G. M., O'Connor, J., Harbinson, M., McCarron, E. P., Duane, F., McCann, C., McKavanagh, P., Johnston, D. I., Erekkath, J., Giacometti, V., **Gavin, A. T.**, McAleese, J., Hounsell, A. R., Cole, A. J., Butterworth, K. T., McGarry, C. K., Hanna, G. G. & Jain, S., Sep 2023, In: Radiotherapy and Oncology.  
[Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: Results from the NI-HEART study - ScienceDirect](https://doi.org/10.1016/j.radonc.2023.109551)
- 6. Factors associated with emergency admission for people dying from cancer in Northern Ireland: an observational data linkage study**  
Mitchell, H., Cairnduff, V., O'Hare, S., Simpson, L., White, R. & Gavin, AT., 31 Oct 2023, In: BMC Health Services Research. 23, 8 p., 1184.  
<https://doi.org/10.1186/s12913-023-10228>
- 7. International benchmarking of childhood cancer survival by stage at diagnosis: The BENCHISTA project protocol**  
Botta L, Gatta G, Didonè F, Lopez Cortes A, Pritchard-Jones K; BENCHISTA Project Working Group. PLoS One. 2022 Nov 3;17(11):e0276997. doi: 10.1371/journal.pone.0276997. eCollection 2022.  
<https://doi.org/10.1371/journal.pone.0276997>

8. **Impact of COVID-19 on cancer incidence, presentation, diagnosis, treatment and survival in Northern Ireland**  
Bennett, D., Murray, I., Mitchell, H., Gavin, A., Donnelly, D. 24 Jan 2024. In: IJC.  
<https://doi.org/10.1002/ijc.34847>
9. **Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study**  
DeAngelis, R., Demuru, E., Baili, P.,EUROCARE-6 Working Group, et al. 30 Jan 2024 In Lancet Oncology.  
[https://doi.org/10.1016/S1470-2045\(23\)00646-0](https://doi.org/10.1016/S1470-2045(23)00646-0)
10. **Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study**  
McPhail S, Barclay M, Johnson SA, Swann R, Alvi R, Barisic A, Bucher O, Creighton N, Denny C A, Dewar R A, Donnelly D W, Dowden J J, Downie L, Finn N, Ga vin A T, Habbous S, Huws D W, May L, McClure C A, Møller B, Zalcborg J R. The Lancet Oncology, March 2024.  
[https://doi.org/10.1016/S1470-2045\(24\)00031-7](https://doi.org/10.1016/S1470-2045(24)00031-7)
11. **Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study**  
McPhail S, Barclay M E, Swann R, Johnson S A, Alvi R, Barisic A, Bucher O, Creighton N, Denny C A, Dewar R A, Donnelly D W, Dowden J J, Downie L, Finn N, Gavin A T, Habbous S, Huws D W, Eshwar Kumar S, May L, McClure C A, Whitfield E. The Lancet Oncology, March 2024.  
[https://doi.org/10.1016/S1470-2045\(24\)00032-9](https://doi.org/10.1016/S1470-2045(24)00032-9)

#### **Other outputs using NICR Data**

- 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis**  
BMJ 2024; 13 March 2024. <https://doi.org/10.1136/bmj-2023-076962>



## APPENDIX E: Requests for Information

### Requests for Information

The NICR provided data and information for 165 requests in 2023, 64 (an increase from 28 in 2022) (38%) general requests and 104 (62%) genetic requests (excluding local genetic requests) (**Figure 5**). A nurse from the Medical Genetics department deals with local genetic requests.

In 2023, 95% of general requests for information were completed within the target 20 working days and 100% of genetic requests for information were completed within the target 10 working days.

30% of general requests were received from academic researchers and charities (combined) (**Figure 6**).

On average general requests took 152 minutes to complete but ranged from 5 minutes to 152 minutes. Genetic requests took an average of 25 minutes to complete however this ranged from 10 minutes to 60 minutes.

**Figure 5: General and Genetic Requests received 2023**





Figure 6: Source of Requests – General



## APPENDIX F: NICR Media

### Media Interactions April 2023 – March 2024

09-05-2023	<b>News Letter (Belfast) Online</b> <a href="#">Pancreatic cancer: NI cases up 86%, audit reveals</a>
09-05-2023	<b>MailOnline's Sport (Newsletter)</b> <a href="#">Pancreatic cancer: NI cases up 86%, audit reveals</a> Link no longer available.
09-05-2023	<b>Irish News (Online)</b> <a href="#">Pancreatic cancer services in north must be strengthened as study shows dramatic rise in cases</a>
05-05-2023	<b>Healthcare-in-Europe.com</b> <a href="#">New online tool reveals vast cancer care inequalities in Europe</a> <small>Lawler, Mark</small>
10-05-2023	<b>Irish News (Circula on 25010)</b> <a href="#">Dramatic rise in pancreatic cancer cases, study shows</a> Link no longer available.
12-05-2023	<b>News Letter (Belfast) (Circula on 7809)</b> <a href="#">Pancreatic cancer: NI cases up 86%, new audit reveals</a> Link no longer available.
18-05-2023	<b>Lurgan Mail (Circula on 623)</b> <a href="#">Pancreatic cancer: NI cases soar by 86%</a> Link no longer available.
18-05-2023	<b>Londonderry Sentinel (Circula on 2500)</b> <a href="#">Pancreatic cancer: NI cases soar by 86%</a> Link no longer available.
18-05-2023	<b>Mid-Ulster Mail (Circula on 6534)</b> <a href="#">Pancreatic cancer: NI cases soar by 86%</a> Link no longer available.
19-05-2023	<b>Ulster Star (Circula on 442)</b> <a href="#">Pancreatic cancer: NI cases soar by 86%</a> Link no longer available.
31-05-2023	<b>India Educa on Diary.in (Circula on 275000)</b> <a href="#">NI audit shows pancreatic cancer spiked in cases- Study</a>
31-05-2023	<b>India Educa on Diary.in</b> <a href="#">NI audit shows pancreatic cancer spiked in cases- Study</a> Link no longer available.

- 05-06-2023 **Belfast Live**  
[Sisters open up on double grief after losing loved ones to 'silent killer'](#)
- 06-06-2023 **Mirror (Online)**  
[Sisters' double grief after losing husband and best friend to same 'silent killer'](#)  
Link no longer available.
- 06-06-2023 **Belfast Telegraph (Circula on 45905)**  
['I want to keep going because I am lucky enough to be here' 'NI just needs to catch up in that respect'](#)  
Link no longer available.
- 07-06-2023 **VNExplorer.net**  
[Two sisters tragically lose loved ones to the same 'silent killer'](#)  
Link no longer available.
- 07-06-2023 **Express.co.uk**  
[Two sisters tragically lose loved ones to the same 'silent killer'](#)  
Link no longer available.
- 08-06-2023 **News Letter (Belfast) Online**  
[Wallace PE teacher Paddy Harrower leaves legacy of gruelling cycling challenge for wife and sister-in-law](#)
- 08-06-2023 **MailOnline's Sport (Newsletter)**  
[Wallace PE teacher Paddy Harrower leaves legacy of gruelling cycling challenge for wife and sister-in-law](#)  
Link no longer available.
- 09-06-2023 **News Letter (Belfast) Online**  
[Two sisters take on gruelling cycling challenge for pancreatic cancer](#)
- 09-06-2023 **MailOnline's Sport (Newsletter)**  
[Two sisters take on gruelling cycling challenge for pancreatic cancer](#)  
Link no longer available.
- 09-06-2023 **News Letter (Belfast) (Circula on 7809)**  
[Brave Paddy to blame for gruelling NI cycling challenge](#)  
Link no longer available.
- 12-06-2023 **PlymouthLive**  
[Sisters lose husband and best friend to 'silent killer' disease](#)
- 12-06-2023 **We love Weymouth (UK) (Facebook Group)**  
[Sisters lose husband and best friend to 'silent killer' disease](#)  
Link no longer available.
- 12-06-2023 **Tribune International (Circula on 962867)**  
[Sisters lose husband and best friend to 'silent killer' disease](#)
- 12-06-2023 **WalesOnline**  
[Sisters lose husband and best friend to 'silent killer' disease](#)

- 30-06-2023** News Bites - Private Companies  
[June 07, 2023: Queens University Belfast: Study by NI Cancer Registry reveals adverse impact of Covid-19 on entire cancer patient pathways](#)  
Link no longer available.
- 10-07-2023** India Educa on Diary.in (Circula on 275000)  
[NI Cancer Registry Research Shows Adverse Impact Of Covid-19 On Entire Cancer Patient Pathways](#)
- 10-07-2023** India Educa on Diary.in  
[NI Cancer Registry Research Shows Adverse Impact Of Covid-19 On Entire Cancer Patient Pathways](#)  
Link no longer available.
- 11-07-2023** India Educa on Diary.in  
[NI Cancer Registry Research Shows Adverse Impact Of Covid-19 On Entire Cancer Patient Pathways](#)  
Link no longer available.
- 01-08-2023** Public Library of Science - PLoS ONE Blog (Circula on : 275000)  
[Exploring the immune microenvironment in small bowel adenocarcinoma using digital image analysis](#)
- 07-09-2023** CE No cias Financieras English (Circula on 962867)  
[Cancer increases 80% in three decades among those under 50 years of age](#)  
Link no longer available.
- 26-10-2023** BBC Radio Foyle (Circula on 524000)  
[BBC Radio Foyle, Evening Extra, 26/10/2023](#)
- 26-10-2023** BBC Radio Ulster (Circula on 524000)  
[BBC Radio Ulster, Evening Extra, 26/10/2023](#)
- 26-10-2023** BBC Radio Foyle (Circula on 524000)  
[BBC Radio Foyle, Evening Extra, 26/10/2023](#)
- 26-10-2023** BBC Radio Ulster (Circula on 524000)  
[BBC Radio Ulster, Evening Extra, 26/10/2023](#)
- 30-10-2023** ExpressHealthcareMgmt.com  
[Newly published statistics show changes in cancer diagnoses during the COVID-19 pandemic](#)  
Link no longer available.
- 30-10-2023** ExpressHealthcareMgmt.com  
[Newly Released Statistics Show Shifts in Cancer Diagnoses During COVID-19](#)  
Link no longer available.
- 30-10-2023** YAHOO! SPORT (UK)  
[Large increases in colon and oesophageal cancer diagnoses in Western Trust](#)  
Link no longer available.
- 30-10-2023** Yahoo! News UK & Ireland  
[Large increases in colon and oesophageal cancer diagnoses in Western Trust](#)  
Link no longer available.

- 30-10-2023**      **Derry Journal (Online)**  
[Large increases in colon and oesophageal cancer diagnoses in Western Trust](#)  
 Link no longer available.
- 31-10-2023**      **Derry Journal (Circula on 27578)**  
[Large increases in colon and oesophageal cancer in Western Trust area](#)  
 Link no longer available.
- 02-11-2023**      **J A M A: Journal of the American Medical Association**  
[Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer](#)
- 02-11-2023**      **Londonderry Sen nel (Circula on 2500)**  
[Large increases in colon and oesophageal cancer in Western Trust area](#)  
 Link no longer available.
- 05-11-2023**      **Downtown Radio (Circula on 307000)**  
[Downtown Radio, Paul Orr, 05/11/2023](#) (Playback Expired)
- 05-11-2023**      **Downtown Radio (Circula on 307000)**  
[Downtown Radio, Neal Mclennand, 05/11/2023](#) (Playback Expired)
- 12-11-2023**      **Sunday Life**  
[Cancer charity cuts to the chase with Titanic Belfast field art](#)  
 Link no longer available.
- 12-11-2023**      **Belfast Telegraph (Online)**  
[Cancer charity cuts to chase with Titanic Belfast grass artwork](#)
- 12-11-2023**      **Sunday Life (Circula on 44155)**  
[Cancer charity cuts to the chase with Titanic Belfast field art](#)  
 Link no longer available.
- 13-11-2023**      **NewsRx COVID-19 Daily**  
[Studies Conducted at Queen's University Belfast on COVID-19 Recently Published \(COVID-19 impact on pathological cancer diagnoses in Netherlands, Aotearoa New Zealand, & N. Ireland\)](#)  
 Link no longer available.
- 17-11-2023**      **India Educa on Diary.in (Circula on 275000)**  
[Researchers at Queen's University Belfast Investigate Breast Cancer Inequalities in Northern Ireland](#)  
*Cardwell, Chris*  
*McShane, Charlene*
- 17-11-2023**      **India Educa on Diary.in**  
[Researchers at Queen's University Belfast Investigate Breast Cancer Inequalities in Northern Ireland](#)  
*Cardwell, Chris*  
*McShane, Charlene*  
 Link no longer available.
- 17-11-2023**      **News Letter (Belfast) (Circula on 7809)**  
[Co Tyrone farmer on surviving pancreatic cancer](#)  
 Link no longer available.

- 18-11-2023 **India Educa on Diary.in (Circula on 275000)**  
[Survey Delves into COVID-19's Impact on Breast Cancer Patients in Northern Ireland and Globally](#)  
*Bennett , Damien*
- 18-11-2023 **India Educa on Diary.in**  
[Survey Delves into COVID-19's Impact on Breast Cancer Patients in Northern Ireland and Globally](#)  
Link no longer available.
- 15-11-2023 **Breast Cancer Now**  
[Press Release Belfast researchers investigate breast cancer inequalities in Northern Ireland \(1\) Researchers are investigating if some women in Northern Ireland experience inequalities in breast cancer care and outcomes, thanks to new funding from Breast](#)
- 30-11-2023 **Big News Network (Circula on 275000)**  
[New pancreatic cancer partnership announced](#)
- 30-11-2023 **News Letter (Belfast) Online**  
[Partnership to improve outcomes for people with pancreatic cancer in NI](#)
- 30-11-2023 **MailOnline's Sport (Newsletter)**  
[Partnership to improve outcomes for people with pancreatic cancer in NI](#)  
Link no longer available.
- 30-11-2023 **Health-ni.gov.uk**  
[New pancreatic cancer partnership announced](#)
- 06-12-2023 **Tyrone Courier (Circula on 10736)**  
[New pancreatic cancer partnership announced](#)  
Link no longer available.
- 25-03-2024 **Pedfire (Circulation : 962867)**  
[Cancer: Number of diagnoses in NI 18-49 age bracket up 20%](#)
- 25-03-2024 **Irish News (Online)**  
[Expert warning after cancer cases for under 50s rise by 20% in Northern Ireland](#)  
*Coleman, Helen*
- 25-03-2024 **BNN.network**  
[Northern Ireland Sees 20% Rise in Young Adult Cancer Diagnoses Over 25 Year](#)  
*Coleman, Helen*
- 25-03-2024 **Aol**  
[Cancer: Number of diagnoses in NI 18-49 age bracket up 20%](#)  
*Coleman, Helen*
- 25-03-2024 **BBC Online**  
[NI sees 20% rise in 18-49 cancer diagnoses](#)  
*Coleman, Helen*
- 26-03-2024 **MSN News US**  
[Expert warning after cancer cases for under 50s rise by 20% in Northern Ireland](#)  
*Coleman, Helen*

26-03-2024

MSN UK

[Expert warning after cancer cases for under 50s rise by 20% in Northern Ireland](#)

*Coleman, Helen*

26-03-2024

Irish News (Circulation : 25010)

['Don't ignore symptoms' as cancer in under 50s up 20%](#)

*Coleman, Helen*